Dr Jo Robson
Find more staff
Role:
Department staff:
Research staff:
- Qualifications:
- MBBS BSc (Hons) PhD FRCP
- Position:
- Professor of Rheumatology
- Department:
- Faculty of Health and Applied Sciences (HAS)
- Telephone:
- +441173281973
- Email:
- Jo.Robson@uwe.ac.uk
About me
I am Professor of Rheumatology with a specialist research and clinical interest in the Systemic Vasculitides, specifically ANCA-associated vasculitis and Giant Cell Arteritis, in particular, patient focused research and outcome measures.
Area of expertise
My research interests are in the development of patient reported outcome measures (PROMS) and health related quality of life in the rare rheumatic diseases including systemic vasculitis and connective tissue diseases. Member of the UWE Musculoskeletal Management Behaviour Change and Outcomes (MAMBO) research group.
I lead the international development of a PROM for ANCA associated vasculitis, the AAV PRO. Underpinning qualitative work was performed with patients from the UK, USA and Canada. Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure (nih.gov)
Validation study was performed in the UK and USA via collaboration with the patient groups Vasculitis UK and the Vasculitis Patient Powered Research Network. Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire - PubMed (nih.gov)
The AAVPRO has been translated into 44 languages and is embedded in international registries and clinical trials. The AAVPRO is free for clinical and academic use. Please see Oxford Innovation for information on how to apply for a licence: https://innovation.ox.ac.uk/licence-details/anca-associated-vasculitis-patient-reported-outcome-aav-pro
I have led the development of a PROM for patients with Giant Cell Arteritis, the GCA PRO. Underpinning qualitative work performed with patients from the UK and Australia. Patient perceptions of health-related quality of life in giant cell arteritis; international development of a disease-specific Patient-Reported Outcome Measure - PubMed (nih.gov). Validation study has been performed in 428 patients via 38 NHS Rheumatology and Ophthalmology sites in the UK. https://academic.oup.com/rheumatology/article/63/1/181/7152987
The GCAPRO is free to use for clinical and academic use, please see below for further information and how to apply for a licence:
I am co-chair of the international Outcome Measures in Rheumatology (OMERACT) Glucocorticoid Impact Working group which has developed a core domain set for what to measure in clinical trials. Glucocorticoids – OMERACT.
Building on this work, I led the development of the Steroid PRO, the first validated and reliable patient reported outcome measure designed to measure the impact of glucocorticoid therapy on patients' wellbeing and health related quality of life. The Steroid PRO has been developed and validated in inflammatory rheumatic conditions, lung, skin and gastroenterological conditions. See below for further information and how to apply for a licence: https://innovation.ox.ac.uk/licence-details/steroid-patient-reported-outcome-measure-steroid-pro
Steering committee chair of the American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS) study, Rheumatology Co-Lead of the UKIVAS Society and member of the European Vasculitis Society (EUVAS).
Consultant Rheumatologist at the Bristol Royal Infirmary Bristol Royal Infirmary - What We Do | University Hospitals Bristol NHS Foundation Trust (uhbristol.nhs.uk)
Publications
Publications loading...